NewAmsterdam Pharma Company NAMS EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's EPS (diluted)?
- NewAmsterdam Pharma Company (NAMS) reported EPS (diluted) of -$0.40 in Q1 2026.
- How has NewAmsterdam Pharma Company's EPS (diluted) changed year-over-year?
- NewAmsterdam Pharma Company's EPS (diluted) decreased by 17.6% year-over-year, from -$0.34 to -$0.40.
- What is the long-term trend for NewAmsterdam Pharma Company's EPS (diluted)?
- Over 4 years (2021 to 2025), NewAmsterdam Pharma Company's EPS (diluted) has grown at a -17.9% compound annual growth rate (CAGR), from -$3.81 to -$1.73.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.